Antibody Response to a Live-Modified Virus Vaccine Against Bovine Viral Diarrhoea in Dairy Cattle in Field Trial

Abstract Background: The objective of the study was to evaluate of the long-term antibody response of dairy cows to a single dose of a commercial modified-live virus (MLV) vaccine against bovine viral diarrhoea (Mucosiffa® CEVA Animal Health, Spain). The study was carried out in a dairy cattle herd counting 290 animals negative for BVDV. The vaccination was implemented in calves from the age of 2 months. Twelve adult lactating cows were randomly selected before study, and blood samples were collected right before the vaccination and then 12 times at 1-month intervals. The serum samples were screened using virus neutralization test (VNT) and ELISA. Results: Both tests showed that antibody titers increased significantly in all animals within the first month post vaccination, and continued to increase until the second (VNT) and third (ELISA) month post vaccination. Antibody titers remained high and stable until the end of the study. Moreover, cows did not show any adverse reactions or clinical symptoms of disease. Conclusion: The results of this study indicated that the administration of one dose MLV vaccine was able to stimulate long-lasting (12-months) and strong antibody response in all vaccinated cows.